Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer
A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.
Diagnosis & Disease Information
Breast Cancer Recurrences Steady Following Therapy Cessation
Women with ER-positive BC who stop therapy after 5 years have steady recurrence rate up to 20 years afterward.
ESR1 Mutations Prevalent in ER+ Metastatic Breast Cancer
ESR1 mutations are more frequent in patients with estrogen receptor (ER)-positive metastatic breast cancer that are treated with aromatase inhibitors, according to recent study data.
Gene Expression Pattern in Surrounding Normal Tissue Linked to Breast Cancer Prognosis
A gene expression pattern in the noncancerous tissues surrounding estrogen receptor-positive breast cancer is associated with lower 10-year survival rates.
- Loading...
Loading...
Next post in Navigation
Loading... 
Loading...